What is the current valuation of the Veterinary Biologics Market as of 2024?

The Veterinary Biologics Market was valued at 27.58 USD Billion in 2024. Read More

What is the projected market size for the Veterinary Biologics Market in 2035?

The market is projected to reach 43.88 USD Billion by 2035. Read More

What is the expected CAGR for the Veterinary Biologics Market during the forecast period 2025 - 2035?

The expected CAGR for the Veterinary Biologics Market during the forecast period 2025 - 2035 is 4.31%. Read More

Which segments are expected to show growth in the Veterinary Biologics Market?

Segments such as Vaccines and Companion Animals are expected to show notable growth. Read More

What are the key types of products in the Veterinary Biologics Market?

Key product types include Vaccines, Antibiotics, Antiparasitics, and Growth Promoters. Read More

How do the revenues from Livestock and Companion Animals compare in the market?

In 2024, revenues from Companion Animals were higher at 17.58 USD Billion compared to 10.0 USD Billion from Livestock. Read More

What are the leading companies in the Veterinary Biologics Market?

Key players include Zoetis, Merck Animal Health, and Boehringer Ingelheim. Read More

What are the primary target diseases addressed by Veterinary Biologics?

Primary target diseases include Viral Infections, Bacterial Infections, and Parasitic Infections. Read More

What sources are utilized in the production of Veterinary Biologics?

Sources include Cell Culture, Inactivated Pathogens, and Recombinant Technologies. Read More

What applications are driving the Veterinary Biologics Market?

Applications driving the market include Disease Prevention, Disease Treatment, and Growth Promotion. Read More

Veterinary Biologics Market

ID: MRFR/HC/26269-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Veterinary Biologics Market Research Report By Type (Vaccines, Antibiotics, Antiparasitics, Growth Promoters), By Species (Livestock, Companion Animals), By Target Disease (Bacterial Infections, Viral Infections, Parasitic Infections, Metabolic Disorders), By Source (Cell Culture, Inactivated Pathogens, Recombinant Technologies), By Application (Disease Prevention, Disease Treatment, Growth Promotion) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Vaccines | |
  2. 4.1.2 Antibiotics | |
  3. 4.1.3 Antiparasitics | |
  4. 4.1.4 Growth Promoters |
2. 4.2 Healthcare, BY Species (USD Billion) | |
  1. 4.2.1 Livestock | |
  2. 4.2.2 Companion Animals |
3. 4.3 Healthcare, BY Target Disease (USD Billion) | |
  1. 4.3.1 Bacterial Infections | |
  2. 4.3.2 Viral Infections | |
  3. 4.3.3 Parasitic Infections | |
  4. 4.3.4 Metabolic Disorders |
4. 4.4 Healthcare, BY Source (USD Billion) | |
  1. 4.4.1 Cell Culture | |
  2. 4.4.2 Inactivated Pathogens | |
  3. 4.4.3 Recombinant Technologies |
5. 4.5 Healthcare, BY Application (USD Billion) | |
  1. 4.5.1 Disease Prevention | |
  2. 4.5.2 Disease Treatment | |
  3. 4.5.3 Growth Promotion |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Zoetis (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Merck Animal Health (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Elanco Animal Health (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Virbac (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Ceva Santé Animale (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Heska Corporation (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Vetoquinol (FR) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Phibro Animal Health (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY SPECIES |
8. 6.5 US MARKET ANALYSIS BY TARGET DISEASE |
9. 6.6 US MARKET ANALYSIS BY SOURCE |
10. 6.7 US MARKET ANALYSIS BY APPLICATION |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY SPECIES |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET DISEASE |
14. 6.11 CANADA MARKET ANALYSIS BY SOURCE |
15. 6.12 CANADA MARKET ANALYSIS BY APPLICATION |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY SPECIES |
19. 6.16 GERMANY MARKET ANALYSIS BY TARGET DISEASE |
20. 6.17 GERMANY MARKET ANALYSIS BY SOURCE |
21. 6.18 GERMANY MARKET ANALYSIS BY APPLICATION |
22. 6.19 UK MARKET ANALYSIS BY TYPE |
23. 6.20 UK MARKET ANALYSIS BY SPECIES |
24. 6.21 UK MARKET ANALYSIS BY TARGET DISEASE |
25. 6.22 UK MARKET ANALYSIS BY SOURCE |
26. 6.23 UK MARKET ANALYSIS BY APPLICATION |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY SPECIES |
29. 6.26 FRANCE MARKET ANALYSIS BY TARGET DISEASE |
30. 6.27 FRANCE MARKET ANALYSIS BY SOURCE |
31. 6.28 FRANCE MARKET ANALYSIS BY APPLICATION |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY SPECIES |
34. 6.31 RUSSIA MARKET ANALYSIS BY TARGET DISEASE |
35. 6.32 RUSSIA MARKET ANALYSIS BY SOURCE |
36. 6.33 RUSSIA MARKET ANALYSIS BY APPLICATION |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY SPECIES |
39. 6.36 ITALY MARKET ANALYSIS BY TARGET DISEASE |
40. 6.37 ITALY MARKET ANALYSIS BY SOURCE |
41. 6.38 ITALY MARKET ANALYSIS BY APPLICATION |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY SPECIES |
44. 6.41 SPAIN MARKET ANALYSIS BY TARGET DISEASE |
45. 6.42 SPAIN MARKET ANALYSIS BY SOURCE |
46. 6.43 SPAIN MARKET ANALYSIS BY APPLICATION |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY SPECIES |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TARGET DISEASE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY SOURCE |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY SPECIES |
55. 6.52 CHINA MARKET ANALYSIS BY TARGET DISEASE |
56. 6.53 CHINA MARKET ANALYSIS BY SOURCE |
57. 6.54 CHINA MARKET ANALYSIS BY APPLICATION |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY SPECIES |
60. 6.57 INDIA MARKET ANALYSIS BY TARGET DISEASE |
61. 6.58 INDIA MARKET ANALYSIS BY SOURCE |
62. 6.59 INDIA MARKET ANALYSIS BY APPLICATION |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY SPECIES |
65. 6.62 JAPAN MARKET ANALYSIS BY TARGET DISEASE |
66. 6.63 JAPAN MARKET ANALYSIS BY SOURCE |
67. 6.64 JAPAN MARKET ANALYSIS BY APPLICATION |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY SPECIES |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TARGET DISEASE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY SOURCE |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY SPECIES |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TARGET DISEASE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY SOURCE |
77. 6.74 MALAYSIA MARKET ANALYSIS BY APPLICATION |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY SPECIES |
80. 6.77 THAILAND MARKET ANALYSIS BY TARGET DISEASE |
81. 6.78 THAILAND MARKET ANALYSIS BY SOURCE |
82. 6.79 THAILAND MARKET ANALYSIS BY APPLICATION |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY SPECIES |
85. 6.82 INDONESIA MARKET ANALYSIS BY TARGET DISEASE |
86. 6.83 INDONESIA MARKET ANALYSIS BY SOURCE |
87. 6.84 INDONESIA MARKET ANALYSIS BY APPLICATION |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY SPECIES |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TARGET DISEASE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY SOURCE |
92. 6.89 REST OF APAC MARKET ANALYSIS BY APPLICATION |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY SPECIES |
96. 6.93 BRAZIL MARKET ANALYSIS BY TARGET DISEASE |
97. 6.94 BRAZIL MARKET ANALYSIS BY SOURCE |
98. 6.95 BRAZIL MARKET ANALYSIS BY APPLICATION |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY SPECIES |
101. 6.98 MEXICO MARKET ANALYSIS BY TARGET DISEASE |
102. 6.99 MEXICO MARKET ANALYSIS BY SOURCE |
103. 6.100 MEXICO MARKET ANALYSIS BY APPLICATION |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY SPECIES |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TARGET DISEASE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY SOURCE |
108. 6.105 ARGENTINA MARKET ANALYSIS BY APPLICATION |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY SPECIES |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET DISEASE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOURCE |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY SPECIES |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TARGET DISEASE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SOURCE |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY SPECIES |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TARGET DISEASE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SOURCE |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY SPECIES |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TARGET DISEASE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY SOURCE |
129. 6.126 REST OF MEA MARKET ANALYSIS BY APPLICATION |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY SPECIES, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY SPECIES, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY SOURCE, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY SOURCE, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY APPLICATION, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY APPLICATION, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY APPLICATION, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY APPLICATION, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY APPLICATION, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY APPLICATION, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY APPLICATION, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY APPLICATION, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY APPLICATION, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY APPLICATION, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY APPLICATION, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY APPLICATION, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY APPLICATION, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY APPLICATION, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY APPLICATION, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY APPLICATION, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY APPLICATION, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY APPLICATION, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY APPLICATION, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY APPLICATION, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY APPLICATION, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY APPLICATION, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY APPLICATION, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY APPLICATION, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY APPLICATION, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY APPLICATION, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY APPLICATION, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY APPLICATION, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY SPECIES, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TARGET DISEASE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY SOURCE, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY APPLICATION, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Vaccines
Antibiotics
Antiparasitics
Growth Promoters

Healthcare By Species (USD Billion, 2025-2035)

Livestock
Companion Animals

Healthcare By Target Disease (USD Billion, 2025-2035)

Bacterial Infections
Viral Infections
Parasitic Infections
Metabolic Disorders

Healthcare By Source (USD Billion, 2025-2035)

Cell Culture
Inactivated Pathogens
Recombinant Technologies

Healthcare By Application (USD Billion, 2025-2035)

Disease Prevention
Disease Treatment
Growth Promotion

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓